Format

Send to

Choose Destination
Future Oncol. 2016 Jan;12(1):107-17. doi: 10.2217/fon.15.284. Epub 2015 Nov 30.

Evolving molecular era of childhood medulloblastoma: time to revisit therapy.

Author information

1
Pediatric Neuro-Oncology, Children's Cancer Hospital, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 87, Houston, TX 77030, USA.

Abstract

Currently medulloblastoma is treated with a uniform therapeutic approach based on histopathology and clinico-radiological risk stratification, resulting in unpredictable treatment failure and relapses. Improved understanding of the biological, molecular and genetic make-up of these tumors now clearly identifies it as a compendium of four distinct subtypes (WNT, SHH, group 3 and 4). Advances in utilization of the genomic and epigenomic machinery have now delineated genetic aberrations and epigenetic perturbations in each subgroup as potential druggable targets. This has resulted in endeavors to profile targeted therapy. The challenge and future of medulloblastoma therapeutics will be to keep pace with the evolving novel biological insights and translating them into optimal targeted treatment regimens.

KEYWORDS:

epigenomic profile; medulloblastoma; molecular subtypes; signaling pathways; targeted therapy; therapeutic resistance

PMID:
26617331
DOI:
10.2217/fon.15.284
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center